TG Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TGTX research report →
Companywww.tgtherapeutics.com
TG Therapeutics, Inc. , a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
- CEO
- Michael S. Weiss
- IPO
- 2010
- Employees
- 352
- HQ
- Morrisville, NY, US
Price Chart
Valuation
- Market Cap
- $6.09B
- P/E
- 12.43
- P/S
- 8.69
- P/B
- 9.85
- EV/EBITDA
- 40.78
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 83.04%
- Op Margin
- 21.35%
- Net Margin
- 65.95%
- ROE
- 87.36%
- ROIC
- 11.13%
Growth & Income
- Revenue
- $616.29M · 87.32%
- Net Income
- $447.18M · 1812.41%
- EPS
- $3.10 · 1837.50%
- Op Income
- $123.32M
- FCF YoY
- 38.40%
Performance & Tape
- 52W High
- $44.65
- 52W Low
- $25.28
- 50D MA
- $34.73
- 200D MA
- $32.10
- Beta
- 1.68
- Avg Volume
- 2.16M
Get TickerSpark's AI analysis on TGTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 28, 26 | Charney Laurence N | other | 30,000 |
| Jan 29, 26 | Charney Laurence N | other | 13,197 |
| Jan 8, 26 | WEISS MICHAEL S | other | 622,000 |
| Jan 8, 26 | Power Sean A | other | 90,000 |
| Nov 24, 25 | Echelard Yann | sell | 5,000 |
| Nov 5, 25 | WEISS MICHAEL S | other | 3,865,126 |
| Nov 5, 25 | WEISS MICHAEL S | other | 803,717 |
| Sep 11, 25 | Lonial Sagar | sell | 20,852 |
| Jun 12, 25 | Echelard Yann | other | 14,718 |
| Jun 13, 25 | Echelard Yann | sell | 10,000 |
Our TGTX Coverage
We haven't published any research on TGTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TGTX Report →